ABDX, an international developer, manufacturer and distributor of rapid tests, recorded a 28.4% increase in H1 2025 revenue to £3.1m (£2.4m H1 2024), led by Regulatory and Product sales. CDMO contract momentum is recovering in H2 following H1 headwinds. ABDX has built strong foundations, investing in product development, US expansion, acquiring regulatory expertise and setting up an analytical laboratory, and in parallel with demand. The company is expanding its service offering, and growing the ....
